Qiagen, Amgen Collaborate to Develop CDx for Investigational NSCLC Drug
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
Biocartis, Amgen Sign CDx Development Deal for Idylla RAS Biomarker Tests
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
High HER3 Levels Identify Colorectal Cancer Patients Who Will Respond to Anti-EGFR Therapy
HER3 mRNA expression analysis can predict colorectal cancer patients with wild-type RAS tumors who will respond to panitumumab, US and UK researchers reported.
Illumina Receives FDA Approval for Companion Dx to Run on MiSeqDx
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.